Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15954349 | 1.00 | ESR1 (0.46) | ESR1ESR2KDM1ACYP3A4MAOA | |
| SCHEMBL30362821 | 1.00 | ESR1 (0.46) | ESR1ESR2KDM1ACYP3A4MAOA | |
| SCHEMBL2717911 | 1.00 | ESR1 (0.46) | ESR1ESR2KDM1ACYP3A4MAOA | |
| SCHEMBL10073997 | 0.87 | MEN1 (0.49) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL30362919 | 0.87 | MEN1 (0.49) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL2719223 | 0.87 | MEN1 (0.49) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL18898168 | 0.87 | MEN1 (0.49) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL15312297 | 0.87 | MEN1 (0.49) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL16999928 | 0.84 | CYP3A4 (0.45) | ESR1ESR2CYP3A4 | |
| SCHEMBL16993473 | 0.84 | CYP3A4 (0.44) | ESR1ESR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230145478-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MEI PHARMA, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230145478-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MEI PHARMA, INC. | 2023-05-11 | — | — | US | disclosed |
| US-11583514-B2 | Isoflavonoid compounds and methods for the treatment of cancer | MEI PHARMA, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2021252776-A1 | COMBINATION THERAPIES | MEI PHARMA, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210000790-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2021-01-07 | — | — | US | disclosed |
| US-20190142790-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20170246142-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2017-08-31 | — | — | US | disclosed |
| US-20170246142-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2017-08-31 | — | — | US | disclosed |
| US-9663484-B2 | Isoflavonoid compounds and methods for the treatment of cancer | MEI PHARMA, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663484-B2 | Isoflavonoid compounds and methods for the treatment of cancer | MEI PHARMA, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20140234295-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140234295-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2012061409-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000790-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | ESR1 57/4885ESR2 22/4885KDM1A 3345/4885 |
| US-20230145478-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | ESR1 57/4885ESR2 22/4885KDM1A 3345/4885 |
| US-20230233519-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL2L2 | ESR1 3784/4885ESR2 2187/4885KDM1A 2264/4885 |
| US-20190142790-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | ESR1 57/4885ESR2 22/4885KDM1A 3345/4885 |
| US-11583514-B2 | Isoflavonoid compounds and methods for the treatment of cancer | BAX, CASP3, API5 | ESR1 57/4885ESR2 22/4885KDM1A 3345/4885 |
| US-20140234295-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | ESR1 57/4885ESR2 22/4885KDM1A 3345/4885 |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | ESR1 57/4885ESR2 22/4885KDM1A 3345/4885 |
| US-20170246142-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | ESR1 57/4885ESR2 22/4885KDM1A 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.